Atherosclerosis and cardiovascular risk reduction with PPAR agonists

被引：19

作者：

Kuusisto J. ^{[1
]}

Andrulionyte L. ^{[1
]}

Laakso M. ^{[1
]}

机构：

[1] Department of Medicine, University of Kuopio, Kuopio University Hospital, FIN-70211 Kuopio

来源：

Current Atherosclerosis Reports | 2007年 / 9卷 / 4期

关键词：

Rosiglitazone; Pioglitazone; PPAR Agonist; Cardiovascular Risk Reduction; Helsinki Heart Study;

D O I：

10.1007/s11883-007-0033-4

中图分类号：

学科分类号：

摘要：

Peroxisome proliferator-activated receptors (PPARs) are transcriptional factors belonging to the nuclear receptor superfamily. Three isoforms, PPARα, PPARγ, and PPARδ, which are encoded by separate genes, have been identified. The PPARs act as gene regulators of various metabolic pathways in energy and lipid metabolism, glucose homeostasis, adipogenesis, and inflammation. Two key classes of synthetic compounds, fibrates and thiazolidinediones (glitazones), activate PPARα and PPARγ, respectively. Both of these drugs have several properties that prevent atherosclerosis in the vascular wall and reduce the levels of risk factors for cardiovascular disease. However, clinical trials have not produced convincing evidence that cardiovascular disease is prevented with the use of PPARα and PPARγ agonists. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：274 / 280

页数：6

共 50 条

[1]

Francis G.A., Annicotte J.S., Auwerx J., PPAR agonists in the treatment of atherosclerosis, Curr Opin Pharmacol, 3, pp. 186-191, (2003)

[2]

Wahli W., Braissant O., Desvergne B., Peroxisome proliferator activated receptors: Transcriptional regulators of adipogenesis, tipid metabolism and more, Chem Biol, 2, pp. 261-266, (1995)

[3]

Kota B.P., Huang T.H., Roufogalis B.D., An overview on biological mechanisms of PPARs, Pharmacol Res, 51, pp. 85-94, (2005)

[4]

Argmann C.A., Cock T.A., Auwerx J., Peroxisome proliferator-activated receptor y. the more the merrier?, EurJ Clin Invest, 35, pp. 82-92, (2005)

[5]

Lee C.H., Olson P., Hevener A., Et al., PPARδ regulates glucose metabolism and insulin sensitivity, Proc Natl Acad Sci U S A, 103, pp. 3444-3449, (2006)

[6]

Berger J.P., Akiyama T.E., Meinke P.T., PPARs: Therapeutic targets for metabolic diseases, Trends Pharmacol Sci, 26, pp. 244-251, (2005)

[7]

Staels B., Vu-Dac N., Kosykh V.A., Et al., Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates, J Clin Invest, 95, pp. 705-712, (1995)

[8]

Chinetti G., Lestavel S., Bocher V., Et al., PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway, Nat Med, 7, pp. 53-58, (2001)

[9]

Marx N., Sukhova G.K., Collins T., Et al., PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells, Circulation, 99, pp. 3125-3131, (1999)

[10]

Touyz R.M., Schiffrin E.L., Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications, Vasc Pharmacol, 45, pp. 19-28, (2006)

← 1 2 3 4 5 →